Development of Thai Spondee Words for SRT Measurement in Children
Keywords:
SRT / speech recognition materials / Thai spondee wordsAbstract
Abstract
Objective: The purpose of this study was to develop a standardized Thai speech material to be used in the measurement of speech recognition threshold (SRT) in children.
Methods: The Thai speech material have been developed according to three essential criteria: word familiarity to the children, phonetic dissimilarity, and homogeneity with respect to basic audibility. The disyllabic words selected from a Thai fundamental word list, used in teaching Thai language at the first level, were analyzed to measure the intensity of each syllable. These spondee words were then assessed for familiarity. As a result, a total of 60 spondee words have been selected to evaluate the threshold of recognition of each word by 30 normal-hearing children.
Results: From the 60 spondee words, there were 25 spondee words, with relatively steep and homogeneous psychometric function slopes, selected to be included in a list of Thai speech material for children. The psychometric functions slopes at the 50% threshold of the final 25 spondee words, were found to have a mean of 10.76 %/dB.
Conclusions: The Thai speech material for children were developed according to the speech material criteria. Hence, this list can be used to evaluate the SRT of normal hearing children.
References
Wittkowsky AK. Warfarin and other coumarin derivatives: pharmacokinetics, pharmacodynamics, and drug interactions. Semin Vasc Med. 2003;3:221-30.
Ansell J, Hirsh J, Poller L, Bussey H, Jacobson A, Hylek E. The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126:204s-33s.
Miners JO, Birkett DJ. Cytochrome P4502C9: an enzyme of major importance in human drug metabolism. Br J Clin Pharmacol. 1998;45:525-38.
Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133:160s- 98s.
Balfour JA, McTavish D, Heel RC. Fenofibrate. Drugs. 1990;40:260-90.
Polnak JF, Delate T, Clark NP. The influence of fibrate initiation on INR and warfarin dose in patients receiving chronic warfarin therapy. J Thromb Thrombolysis. 2018;46:264-70.
Leonard CE, Brensinger CM, Bilker WB, Kimmel SE, Han X, Nam YH, et al. Gastrointestinal bleeding and intracranial hemorrhage in concomitant users of warfarin and antihyperlipidemics. Int J Cardiol Heart Vasc. 2017;228:761-70.
Ascah KJ, Rock GA, Wells PS. Interaction between fenofibrate and warfarin. Ann Pharmacother. 1998;32:765-8.
Guo C, Xue S, Zheng X, Lu Y, Zhao D, Chen X, et al. The effect of fenofibric acid on the pharmacokinetics and pharmacodynamics of warfarin in rats. Xenobiotica. 2018;48:400-6.
El-Helou N, Al-Hajje A, Ajrouche R, Awada S, Rachidi S, Zein S, et al. Adverse drug events associated with vitamin K antagonists: factors of therapeutic imbalance. Vasc Health Risk Manag. 2013;9:81-8.
Juurlink DN. Drug interactions with warfarin: what clinicians need to know. CMAJ. 2007;177:369-71.
Balfour JA, McTavish D, Heel RC. Fenofibrate. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in dyslipidaemia. Drugs. 1990;40:260-90.
Kim KY, Mancano MA. Fenofibrate potentiates warfarin effects. Ann Pharmacother. 2003;37:212-5.
Breault R, Klakowicz A, George-Phillips K, Bungard T. Warfarin dosing after initiation of fenofibrate. Can J Hosp Pharm. 2005;58.
Aldridge MA, Ito MK. Fenofibrate and Warfarin Interaction. Pharmacotherapy. 2001;21:886-9.
